Submit Manuscript  

Article Details


Potential Applications of Induced Pluripotent Stem Cells for Cardiovascular Diseases

Author(s):

Xiaotong Wang, Ye Yuan, Zhenbo Han, Ying Yu, Zihang Xu and Benzhi Cai*   Pages 1 - 13 ( 13 )

Abstract:


Owning the high incidence and disability rate in modern society, to be expected, cardiovascular diseases (CVDs) have become the global and most fatal cause nowadays. Currently, induced pluripotent stem cells (iPSCs), with the potential to form fresh myocardium and better safety than other stem cells, existed widely in the CVD therapy studies. Simultaneously, iPSC-derived cardiomyocytes (CMs), as a novel disease model, appear to play a significant role in new drug screening, drug safety assessment, along with the pathological mechanisms of diseases. Based on rigorous molecular and functional characterization, the accuracy of experimental researches are guaranteed and thus several underlying pathogenesis for the treatment of CVDs by iPSCs were published, such as enrichment of paracrine factors, regulation of miRNAs, mechanical support of new tissues, activation of specific pathways and specific enzymes, etc. Furthermore, a few chemical small molecules and suitable biological scaffolds remained contributors in enhancing the efficiency of iPSC transplantation. This article reviews the development courses and limitations of iPSCs in CVD therapy, and summarizes in category the latest research achievements from iPSCs.

Keywords:

Induced pluripotent stem cells, cell therapy, cardiovascular disease

Affiliation:

Department of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China; and Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, Department of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China; and Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, Department of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China; and Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, Department of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China; and Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, Department of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China; and Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081, Department of Clinical Pharmacy, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China; and Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin 150081



Read Full-Text article